Published in Br J Cancer on May 06, 2014
Loss of Stromal IMP1 Promotes a Tumorigenic Microenvironment in the Colon. Mol Cancer Res (2015) 1.44
NEAT expression is associated with tumor recurrence and unfavorable prognosis in colorectal cancer. Oncotarget (2015) 1.13
Resistance to targeted cancer drugs through hepatocyte growth factor signaling. Cell Cycle (2014) 0.84
Association between serum ligands and the skin toxicity of anti-epidermal growth factor receptor antibody in metastatic colorectal cancer. Cancer Sci (2015) 0.81
Determinants of metastatic competency in colorectal cancer. Mol Oncol (2017) 0.80
HGF-MET in cancer progression and biomarker discovery. Cancer Sci (2017) 0.80
Understanding and Targeting MET Signaling in Solid Tumors - Are We There Yet? J Cancer (2016) 0.79
Inhibition of pro-HGF activation by SRI31215, a novel approach to block oncogenic HGF/MET signaling. Oncotarget (2016) 0.77
Prognostic and Predictive Significance of Stromal Fibroblasts and Macrophages in Colon Cancer. Biomark Cancer (2015) 0.77
Phosphoproteomics Reveals MAPK Inhibitors Enhance MET- and EGFR-Driven AKT Signaling in KRAS-Mutant Lung Cancer. Mol Cancer Res (2016) 0.77
Serum level of hepatocyte growth factor is a novel marker of predicting the outcome and resistance to the treatment with trastuzumab in HER2-positive patients with metastatic gastric cancer. Oncotarget (2016) 0.77
Prognostic role of ERBB2, MET and VEGFA expression in metastatic colorectal cancer patients treated with anti-EGFR antibodies. Br J Cancer (2016) 0.76
Recent Advances in Targeting the EGFR Signaling Pathway for the Treatment of Metastatic Colorectal Cancer. Int J Mol Sci (2017) 0.75
Biomarkers of skin toxicity induced by anti-epidermal growth factor receptor antibody treatment in colorectal cancer. World J Gastroenterol (2016) 0.75
NDRG4 stratifies the prognostic value of body mass index in colorectal cancer. Oncotarget (2016) 0.75
Hepatocyte Growth Factor, a Key Tumor-Promoting Factor in the Tumor Microenvironment. Cancers (Basel) (2017) 0.75
Hepatocyte growth factor is a prognostic marker in patients with colorectal cancer: a meta-analysis. Oncotarget (2017) 0.75
Hepatocyte Growth Factor/c-Met Signaling in Head and Neck Cancer and Implications for Treatment. Cancers (Basel) (2017) 0.75
Influence of the HER receptor ligand system on sensitivity to cetuximab and trastuzumab in gastric cancer cell lines. J Cancer Res Clin Oncol (2016) 0.75
Predictive blood plasma biomarkers for EGFR inhibitor-induced skin rash. Oncotarget (2017) 0.75
Quantitative proteomic profiling of paired cancerous and normal colon epithelial cells isolated freshly from colorectal cancer patients. Proteomics Clin Appl (2016) 0.75
Global cancer statistics. CA Cancer J Clin (2011) 185.92
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med (2004) 49.02
MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science (2007) 32.68
Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med (2009) 22.23
ERBB receptors and cancer: the complexity of targeted inhibitors. Nat Rev Cancer (2005) 16.73
Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol (2008) 15.17
Met, metastasis, motility and more. Nat Rev Mol Cell Biol (2003) 14.30
Cetuximab for the treatment of colorectal cancer. N Engl J Med (2007) 13.39
Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. Lancet Oncol (2010) 13.25
Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab. J Clin Oncol (2007) 9.29
Wnt activity defines colon cancer stem cells and is regulated by the microenvironment. Nat Cell Biol (2010) 7.73
The EGFR family and its ligands in human cancer. signalling mechanisms and therapeutic opportunities. Eur J Cancer (2001) 5.96
Hepatocyte growth factor is a potent angiogenic factor which stimulates endothelial cell motility and growth. J Cell Biol (1992) 5.04
Hepatocyte growth factor induces gefitinib resistance of lung adenocarcinoma with epidermal growth factor receptor-activating mutations. Cancer Res (2008) 4.30
Mechanisms of acquired resistance to cetuximab: role of HER (ErbB) family members. Oncogene (2008) 4.13
Epidermal growth factor receptor targeting in cancer. Semin Oncol (2006) 3.84
KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer. Br J Cancer (2009) 3.73
The epidermal growth factor receptor pathway: a model for targeted therapy. Clin Cancer Res (2006) 3.17
Amphiregulin and epiregulin mRNA expression in primary tumors predicts outcome in metastatic colorectal cancer treated with cetuximab. J Clin Oncol (2009) 2.92
Amplification of the MET receptor drives resistance to anti-EGFR therapies in colorectal cancer. Cancer Discov (2013) 2.87
ErbB/HER ligands in human breast cancer, and relationships with their receptors, the bio-pathological features and prognosis. Ann Oncol (2007) 2.18
Epidermal growth factor receptor (EGFR) ubiquitination as a mechanism of acquired resistance escaping treatment by the anti-EGFR monoclonal antibody cetuximab. Cancer Res (2007) 2.14
Differential effects of EGFR ligands on endocytic sorting of the receptor. Traffic (2009) 1.83
Epiregulin is a potent pan-ErbB ligand that preferentially activates heterodimeric receptor complexes. J Biol Chem (1998) 1.81
PIK3CA exon 20 mutations as a potential biomarker for resistance to anti-EGFR monoclonal antibodies in KRAS wild-type metastatic colorectal cancer: a systematic review and meta-analysis. Ann Oncol (2011) 1.61
Targeting the HGF/Met signaling pathway in cancer therapy. Expert Opin Ther Targets (2012) 1.45
LGR5-positive colon cancer stem cells interconvert with drug-resistant LGR5-negative cells and are capable of tumor reconstitution. Stem Cells (2012) 1.36
The biological role of HGF-MET axis in tumor growth and development of metastasis. Front Biosci (2008) 1.32
Epidermal growth factor receptor regulates MET levels and invasiveness through hypoxia-inducible factor-1alpha in non-small cell lung cancer cells. Oncogene (2010) 1.17
Expression of epiregulin, a novel epidermal growth factor ligand associated with prognosis in human oral squamous cell carcinomas. Oncol Rep (2008) 1.04
MicroRNAs targeting EGFR signalling pathway in colorectal cancer. J Cancer Res Clin Oncol (2013) 0.91
Expression of betacellulin, heparin-binding epidermal growth factor and epiregulin in human malignant fibrous histiocytoma. Anticancer Res (2004) 0.83